Legacy Capital Group California Inc. Sells 5,229 Shares of Johnson & Johnson $JNJ

Legacy Capital Group California Inc. cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 38.3% in the 3rd quarter, Holdings Channel reports. The firm owned 8,416 shares of the company’s stock after selling 5,229 shares during the period. Legacy Capital Group California Inc.’s holdings in Johnson & Johnson were worth $1,561,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of JNJ. Modern Wealth Management LLC lifted its position in shares of Johnson & Johnson by 10.8% during the 3rd quarter. Modern Wealth Management LLC now owns 44,105 shares of the company’s stock worth $8,178,000 after buying an additional 4,291 shares during the last quarter. Neo Ivy Capital Management grew its position in Johnson & Johnson by 37.3% in the third quarter. Neo Ivy Capital Management now owns 15,058 shares of the company’s stock valued at $2,792,000 after acquiring an additional 4,094 shares during the last quarter. Intellectus Partners LLC grew its position in Johnson & Johnson by 1.2% in the third quarter. Intellectus Partners LLC now owns 10,061 shares of the company’s stock valued at $1,866,000 after acquiring an additional 123 shares during the last quarter. Foster Dykema Cabot & Partners LLC raised its stake in Johnson & Johnson by 16.4% during the third quarter. Foster Dykema Cabot & Partners LLC now owns 6,414 shares of the company’s stock worth $1,189,000 after acquiring an additional 902 shares in the last quarter. Finally, Guardian Capital LP lifted its holdings in shares of Johnson & Johnson by 6.5% in the third quarter. Guardian Capital LP now owns 147,984 shares of the company’s stock worth $27,439,000 after acquiring an additional 9,071 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of research analyst reports. Scotiabank reiterated an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, January 22nd. Wall Street Zen lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, December 11th. Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a research note on Wednesday, January 28th. Finally, Rothschild & Co Redburn raised their price objective on Johnson & Johnson from $180.00 to $210.00 and gave the company a “neutral” rating in a report on Thursday, February 19th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $234.87.

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 1,322 shares of the business’s stock in a transaction on Friday, February 20th. The shares were sold at an average price of $245.66, for a total value of $324,762.52. Following the transaction, the executive vice president owned 25,447 shares in the company, valued at $6,251,310.02. The trade was a 4.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 30,142 shares of company stock valued at $7,360,528 in the last three months. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

JNJ stock opened at $240.57 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $251.71. The company has a market capitalization of $579.75 billion, a P/E ratio of 21.77, a PEG ratio of 2.37 and a beta of 0.34. The company has a fifty day moving average price of $228.36 and a 200-day moving average price of $204.01.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The business had revenue of $24.28 billion during the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. As a group, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.2%. Johnson & Johnson’s dividend payout ratio is presently 47.06%.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approval of TECVAYLI® plus DARZALEX FASPRO® for relapsed/refractory multiple myeloma — approval was based on strong Phase 3 results showing significant improvements in progression‑free and overall survival, and J&J positions the combo as a potential new standard of care as early as second line. This materially expands the company’s oncology commercial opportunity and is the main catalyst lifting sentiment. PR Newswire: J&J FDA approval
• Positive Sentiment: Inclusion in dividend lists / dividend‑aristocrat coverage — recent articles cite JNJ among Dividend Kings/Aristocrats, reinforcing its appeal to income and defensive investors given decades of payout growth. That supports demand from dividend‑focused funds and conservative investors. 24/7 Wall St.: Dividend Kings
• Neutral Sentiment: JPMorgan raised its price target from $225 to $250 but kept a “neutral” rating — the PT lift signals modest analyst upside recognition of recent catalysts, though the unchanged rating tempers near‑term conviction. Benzinga: JPMorgan price target
• Neutral Sentiment: Direct‑to‑consumer website launch — J&J rolled out a site to sell certain drugs directly to U.S. patients who are uninsured or pay out‑of‑pocket; potential to improve access and margin over time, but impact on revenue is unclear near term. Reuters: direct-to-consumer site
• Negative Sentiment: $65 million Tracleer antitrust settlement — two J&J units agreed to pay $65M to resolve a class action alleging overcharges for the pulmonary hypertension drug; materiality is modest relative to J&J’s scale but it is a headline legal expense. Reuters: Tracleer settlement
• Negative Sentiment: Near‑term price volatility / recent pullback — a few market reports noted a day‑over‑day decline ahead of the approval news; investors should be prepared for swings as the market digests launch timing, uptake and reimbursement dynamics. Zacks: recent decline

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.